Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
NCT07355699Phase 4Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Nov 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of orelabrutinib in marginal zone lymphoma (MZL) (2 arms), sponsored by Beijing Tongren Hospital. Primary endpoint: Overall Response Rate at 21 weeks. Started Nov 2025; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT07355699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07355699.